Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plamotamab Combo in R/R DLBCL
NCT05328102Phase 2Terminated
- Sponsor
- Xencor
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of Plamotamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Xencor. Started Apr 2022; status: terminated.
02
Drugs
Plamotamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05328102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328102.